ReviewInfectious agents and cancer2025
Systematic review and meta-analysis of chemotherapy-induced adverse drug reactions among children with cancer in Africa.
Review in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing Endophytic Fungi as a Sustainable Source of Novel Anticancer Agents: Opportunities, Challenges, and Future Directions.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral systematic reviews have looked at chemotherapy-related toxicities in children with cancer worldwide. In African settings, the rates of ADRs may differ. There is no robust, quantitative estimate of the overall pooled prevalence of chemotherapy-related ADRs among African pediatric oncology patients. Both hematologic and solid tumor patients were included in the analysis. Hence, this study aimed to assess the pooled prevalence of chemotherapy-related adverse drug events among children with all cancer types in Africa.
methodsWe used a comprehensive search of articles using different databases (7 databases) such as Google Scholar, Cochrane Library, Science Direct, Web of Sciences, Scopus, EMBASE, and PubMed to explore relevant studies. Studies published until November 16, 2025 included in the study. The quality of the included studies was assessed using the Newcastle– Ottawa Quality Assessment Scale. Data was extracted with Microsoft Excel and analyzed using STATA version 17 software. Random effect meta-regression analysis at 95% CI was used to assess the pooled prevalence of chemotherapy-related adverse drug events among children with cancer in Africa. Heterogeneity was determined using the I2 statistic, and publication bias was evaluated with a funnel plot and Egger test.
resultThe pooled prevalence of chemotherapy-induced adverse drug events among pediatric cancer patients in Africa from 9 studies revealed that 62.03% (95%CI: 36.93–87.13) and with (I2 = 99.4, P = 0.000). A Subgroup meta-analysis showed comparatively less heterogeneity in other African countries (I2 = 88.2%, p = 0.000) as compared to studies conducted in Ethiopia (I2 = 99%, P-value = 0.000). Moreover, subgroup meta-analysis showed that there was a difference in the strength of heterogeneity between articles published before 2020(I2 = 99.8%, P-value = 0.000) and after 2020 (I2 = 97.4%, p = 0.000).
conclusionThe burden of chemotherapy-related adverse drug reactions was found to be high. Health care professionals involved in cancer treatment should be prepared to deal with chemotherapy-related adverse drug reactions. Routine ADR surveillance should be integrated into pediatric oncology wards in Africa. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.